Expert Interview
A look at IMU-838 (vidofludimus calcium) as a potential therapy for moderate-severe ulcerative colitis ahead of the phase 2 readout of the CALDOSE-1 trial.
Ticker(s): IMUXInstitution: Texas Children's Hospital
- Associate Professor of Pediatrics (Pediatric Gastroenterology), Director of the Pediatric Inflammatory Bowel Disease Program & Medical Director of the Fecal Microbiota Transplantation program at Texas Children's Hospital, Baylor College of Medicine (BCM).
- Currently manages 200 patients with UC; special interest in IBD (including Crohn's disease and ulcerative colitis), and Clostridium difficile infection.
- Research focuses on the microbiome and the environmental (nutritional and epigenetic) origins of IBD.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
